A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C-Reference-Cited by-同舟云学术

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Published:2007-11 Issue:5 Volume:52 Page:1398-1406
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Ojea Antonio,Nogueira José Luís,Solsona Eduardo,Flores Nicolás,Gómez Jesús María Fernández,Molina Jesús Rodríguez,Chantada Venancio,Camacho José Emilio,Piñeiro Luís Martínez,Rodríguez Rafael Hernandez,Isorna Santiago,Blas Miguel,Martínez-Piñeiro José A.,Madero Rosario

Publisher

Elsevier BV

Subject

Urology

Reference19 articles.

1. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer;Lum;J Natl Cancer Inst,1991

2. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer;Lamm;J Urol,1992

3. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder;Lamm;J Urol,1995

4. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials;Shelley;BJU Int,2004

5. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2002

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

2. Mitomycin C vs. Bacillus Calmette–Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients—A comparative analysis from a single center;Urologic Oncology: Seminars and Original Investigations;2024-07

3. The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis;European Urology Oncology;2024-06

4. Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer;Advanced Materials;2024-02-16

5. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile;Bladder Cancer;2023-12-13